Instil Bio Soars 41.04% on New CMO Appointment

On June 2, 2025, Instil Bio's stock surged by 41.04% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Instil Bio has announced the appointment of Jamie Freedman, M.D., Ph.D., as its new Chief Medical Officer. Dr. Freedman brings over two decades of experience in hematology-oncology and has a proven track record in drug development and regulatory approvals. This strategic move is aimed at advancing the company's lead candidate, AXN-2510, which has shown promising results in clinical trials.

The appointment of Dr. Freedman is seen as a positive development for Instil Bio, as it strengthens the company's leadership team and enhances its capabilities in medical research and development. Investors are optimistic about the potential impact of Dr. Freedman's expertise on the company's pipeline and future growth prospects.